<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03457623</url>
  </required_header>
  <id_info>
    <org_study_id>38RC16.045</org_study_id>
    <nct_id>NCT03457623</nct_id>
  </id_info>
  <brief_title>Batch n ° 2 of the Public Market Evaluation &quot;Medico-economic Demonstrator IsereADOM&quot;</brief_title>
  <acronym>CardIC</acronym>
  <official_title>Medico-economic Evaluation of a &quot;IsereADOM&quot; Package of Services Versus Conventional Health and Social Monitoring, in the Care of a Population of People With Heart Failure in Isère.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Conseil Départemental de l'Isère</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to evaluate the health and social benefit of innovative management
      - IsereADOM - versus conventional follow-up in patients with heart failure.

      There is a medico-economic goal too, is to perform a cost-utility analysis of the service
      bundle (IsereADOM) versus conventional 6-month community-based follow-up in a population with
      heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the effectiveness of a service package compared to conventional follow-up in people with heart failure.</measure>
    <time_frame>6 months</time_frame>
    <description>The outcome measure is the number of hospitalization</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Innovative supported</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to usual care, patients benefit from connected tools (overpoise, sphygmomanometer...), physical activity, a strong accompaniment with a referent person</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional supported</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients benefit from usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Innovative Supported</intervention_name>
    <description>addition of connected tools and stronger accompaniment to improve quality of life</description>
    <arm_group_label>Innovative supported</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient diagnosed with heart failure confirmed by a cardiologist;

          -  Patient with functional NYHA II, III, IV staining;

          -  Patient domiciled in a geographical area allowing access to the IsèreADOM service
             package: Grenoble agglomeration, Vercors, Bièvre Valloire, Porte des Alpes;

          -  Patient who can be followed regularly for 6 months;

          -  Patient who can benefit from RESIC-type health education;

          -  Presence of a caregiver referent of proximity (family or other) according to
             appreciation of the investigating doctor in case of cognitive disorders;

          -  Patient affiliated with social security or beneficiary of such a scheme;

          -  Patient able to read, write and understand French;

          -  Patient having signed informed consent to participate.

        Exclusion Criteria:

          -  Patient with peritoneal dialysis or haemofiltration;

          -  Patient with severe co-morbidity with poor short-term prognosis: mortality &lt;6 months;

          -  Patient with future surgical etiologic treatment: prosthetic valve, revascularization
             procedure, TAVI or MITRACLIP;

          -  Patient residing in a nursing home or institution for dependent person;

          -  Persons referred to in Articles L1121-5 to L1121-8 of the CSP (corresponds to all
             persons protected: pregnant woman, parturient, mother who is breastfeeding, person
             deprived of liberty by judicial or administrative decision, person subject of a legal
             protection measure).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muriel SALVAT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Grenoble - Alpes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marion Proust</last_name>
    <phone>+33 (0)4 76 76 73 12</phone>
    <email>mproust@chu-grenoble.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Groupe Hospitalier Mutualiste</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Proust</last_name>
    </contact>
    <investigator>
      <last_name>Damien GUIJARRO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble-Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion Proust</last_name>
    </contact>
    <investigator>
      <last_name>Muriel Salvat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11):e442.</citation>
    <PMID>17132052</PMID>
  </reference>
  <reference>
    <citation>Desai AS, Stevenson LW. Rehospitalization for heart failure: predict or prevent? Circulation. 2012 Jul 24;126(4):501-6. doi: 10.1161/CIRCULATIONAHA.112.125435.</citation>
    <PMID>22825412</PMID>
  </reference>
  <reference>
    <citation>McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012 Aug;14(8):803-69. doi: 10.1093/eurjhf/hfs105. Erratum in: Eur J Heart Fail. 2013 Mar;15(3):361-2.</citation>
    <PMID>22828712</PMID>
  </reference>
  <reference>
    <citation>Desai AS. The three-phase terrain of heart failure readmissions. Circ Heart Fail. 2012 Jul 1;5(4):398-400. doi: 10.1161/CIRCHEARTFAILURE.112.968735.</citation>
    <PMID>22811548</PMID>
  </reference>
  <reference>
    <citation>Takeda A, Taylor SJ, Taylor RS, Khan F, Krum H, Underwood M. Clinical service organisation for heart failure. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD002752. doi: 10.1002/14651858.CD002752.pub3. Review.</citation>
    <PMID>22972058</PMID>
  </reference>
  <reference>
    <citation>Krumholz HM, Merrill AR, Schone EM, Schreiner GC, Chen J, Bradley EH, Wang Y, Wang Y, Lin Z, Straube BM, Rapp MT, Normand SL, Drye EE. Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes. 2009 Sep;2(5):407-13. doi: 10.1161/CIRCOUTCOMES.109.883256. Epub 2009 Jul 9.</citation>
    <PMID>20031870</PMID>
  </reference>
  <reference>
    <citation>Powell LH, Calvin JE Jr, Richardson D, Janssen I, Mendes de Leon CF, Flynn KJ, Grady KL, Rucker-Whitaker CS, Eaton C, Avery E; HART Investigators. Self-management counseling in patients with heart failure: the heart failure adherence and retention randomized behavioral trial. JAMA. 2010 Sep 22;304(12):1331-8. doi: 10.1001/jama.2010.1362.</citation>
    <PMID>20858878</PMID>
  </reference>
  <reference>
    <citation>Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ. 2005 May;14(5):487-96.</citation>
    <PMID>15497198</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2018</study_first_submitted>
  <study_first_submitted_qc>February 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>February 28, 2018</last_update_submitted>
  <last_update_submitted_qc>February 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

